B3GAT1 (NK-1) Mouse mAb #25002
- IHC
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | |
| Source/Isotype | Mouse IgM |
Application Key:
- IHC-Immunohistochemistry
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| IHC Leica Bond | 1:100 - 1:400 |
| Immunohistochemistry (Paraffin) | 1:100 - 1:400 |
Storage
Protocol
Specificity / Sensitivity
B3GAT1 (NK-1) Mouse mAb recognizes endogenous levels of B3GAT1 protein.
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with B3GAT1 expressing human peripheral blood mononuclear cells.
Background
Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 (B3GAT1), also known as beta-1,3-glucuronyltransferase 1 and glucuronosyltransferase P, is a type II membrane protein enzyme encoded by the B3GAT1 gene. This gene is localized on the 11q25 chromosome and is a member of the glucuronyltransferase gene family (1). B3GAT1 is one of the enzymes involved in the biosynthesis of carbohydrate epitope human natural killer-1 (HNK-1), also known as CD57 and Leu7 (2). B3GAT1 catalyzes the glucuronyl transfer reaction that adds a glucuronic acid to the terminal N-acetyllactosamine (Lac) disaccharide to form the CD57 epitope on a variety of proteins, lipids, and chondroitin sulfate proteoglycans at the cell surface (3). CD57 is present on a subset of peripheral blood lymphocytes, including NK cells and CD8+ T cells, as well as neural cells and striated muscle (4-7). The CD57 epitope may play a role in neural cell adhesion (8), and characterizes unique maturation states in T and NK cells (9,10).
- Mitsumoto, Y. et al. (2000) Genomics 65, 166-73.
- Abo, T. and Balch, C.M. (1981) J Immunol 127, 1024-9.
- Górska, A. et al. (2016) Arch Immunol Ther Exp (Warsz) 64, 497-503.
- Kared, H. et al. (2016) Cancer Immunol Immunother 65, 441-52.
- Lopez-Vergès, S. et al. (2010) Blood 116, 3865-74.
- Focosi, D. et al. (2010) J Leukoc Biol 87, 107-16.
- Mechtersheimer, G. et al. (1991) Cancer Res 51, 1300-7.
- Künemund, V. et al. (1988) J Cell Biol 106, 213-23.
- Sze, D.M. et al. (2001) Blood 98, 2817-27.
- Nielsen, C.M. et al. (2013) Front Immunol 4, 422.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.